Patent Law Weblog
recent posts
- Quo Vadis mRNA Vaccine Technology? The State of the IP Lawsuits
- Moderna Settles Patent Litigation with Arbutus et al.
- USPTO and DOJ Statement of Interest in Collision Communications: Another Thumb on the Scale in Favor of NPE Patent Plaintiffs
- Oasis Tooling, Inc. v. Siemens Industry Software Inc. (Fed. Cir. 2026)
- Why AI Will Not Take Over the World
about
Category: Uncategorized
-
Technology Transfer Tactics will be offering a webinar entitled "Patent 'Trolls' Under Fire: Strategies, Tactics and Legislation Impacting University Patents & Licensing" on October 22, 2013 from 1:00 to 2:00 pm (Eastern). Scott A. McKeown and Kevin B. Laurence of Oblon Spivak will cover the following topics: • The latest on anti-troll initiatives, including executive…
-
Practising Law Institute (PLI) will be holding its Fundamentals of Patent Prosecution 2013: A Boot Camp for Claim Drafting & Amendment Writing seminar on May 14-16, 2013 in Chicago, IL, on June 12-14, 2013 in New York, NY, and on July 10-12, 2013 in San Francisco, CA. The three-day program, which is directed to patent…
-
By Donald Zuhn — One day after the Supreme Court reversed the Federal Circuit in Mayo Collaborative Services v. Prometheus Laboratories, Inc., finding Prometheus' diagnostic method claims to be invalid for "effectively claim[ing] underlying laws of nature," the U.S. Patent and Trademark Office issued a memorandum to its examining corps providing the Office's preliminary guidance…
-
By Kevin E. Noonan — One of the longest patent law sagas has apparently reached an end. As announced by The Medicines Company (MDCO) today, the drug developer has reached a settlement of litigation with APP Pharmaceuticals over Angiomax® (bivalirudin). Most important for MDCO, the settlement dismisses APP's appeal of the denial of its motion…
-
By James DeGiulio — Since 2009, we have been tracking the story surrounding Genzyme's enzyme replacement drug Fabrazyme, which started with a problem at Genzyme's manufacturing facilities and led to nationwide shortages of the drug. These shortages prompted Fabry patients to petition the Department of Health and Human Services to exercise march-in rights under the…
-
By Kevin E. Noonan — The Biotechnology Industry Organization (BIO) sent a letter today to Attorney General Eric H. Holder, Jr. and Acting Solicitor General Neal K. Kaytal regarding the Supreme Court's request for the government's views on the questions presented by petitioners in Microsoft v. i4i (the Court granted Microsoft's petition for writ of certiorari…
-
By Donald Zuhn — In a joint press release issued on Monday, the U.S. Patent and Trademark Office and European Patent Office announced that the two offices would be working together to develop a joint patent classification system. One of the goals of the joint effort will be to align the EPO classification and U.S.…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Galderma Laboratories LP et al. v. Actavis Mid Atlantic LLC1:10-cv-00887; filed October 15, 2010 in the District Court of Delaware • Plaintiffs: Galderma Laboratories LP; Galderma SA; Galderma Research and Development SNC• Defendant: Actavis Mid Atlantic…
-
By James DeGiulio — As the Patent Reform Act of 2010 makes its way through the Senate, various groups continue to make their positions known on provisions contained within the legislation. (For a detailed summary of the bill, see "Senate Leadership Unveils Details of Patent Reform Agreement.") On September 12, the Intellectual Property Owners Association…
-
By James DeGiulio — Genzyme's manufacturing problems with their $300,000 per year drug Fabrazyme have prompted patients who depend on the enzyme replacement drug to ask that Health and Human Services (HHS) Secretary Kathleen Sebelius exercise the government's "march-in rights" under the Bayh-Dole Act. The 1980 law empowers the federal agency funding the research, here…
Patent Docs 